Announcements Trials
Browse Landscape

Phase

Phase 3 18Phase 1 18Phase 2 17Phase 1/2 10Phase 4 2Phase 2/3 2

Status

Not yet recruiting 2

Sponsor Class

OTHER 3INDUSTRY 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Sarcoma 1

Conditions

Gastrointestinal Stromal Tumors 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 29Carboplatin 28Gemcitabine 27Paclitaxel 26pembrolizumab 24Capecitabine 16Pemetrexed 15Bevacizumab 15Docetaxel 14Oxaliplatin 13Fluorouracil 12Drug Therapy 12Nivolumab 10130-nm albumin-bound paclitaxel 9Trastuzumab 8anlotinib 7Injections 7Rituximab 6venetoclax 5atezolizumab 5Temozolomide 5Leucovorin 5Ipilimumab 5Lenalidomide 4Irinotecan 4Interferon alpha-2 4Folfox protocol 4Dexamethasone 4Azacitidine 4Albumin-Bound Paclitaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × regorafenib × Clear all
NCT07379047 2026-04-24

GISTAR-1

Ningbo Newbay Technology Development Co., Ltd

Phase 2/3 Not yet recruiting
255 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT07392866 2026-02-09

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 2/3 Not yet recruiting
120 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡